[go: up one dir, main page]

MX2007006775A - Composiciones estables de fenofibrato con esteres de acido graso. - Google Patents

Composiciones estables de fenofibrato con esteres de acido graso.

Info

Publication number
MX2007006775A
MX2007006775A MX2007006775A MX2007006775A MX2007006775A MX 2007006775 A MX2007006775 A MX 2007006775A MX 2007006775 A MX2007006775 A MX 2007006775A MX 2007006775 A MX2007006775 A MX 2007006775A MX 2007006775 A MX2007006775 A MX 2007006775A
Authority
MX
Mexico
Prior art keywords
fenofibrate
fatty acid
acid esters
stable compositions
solvent system
Prior art date
Application number
MX2007006775A
Other languages
English (en)
Inventor
George Bobotas
Roelof M L Rongen
Original Assignee
Reliant Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reliant Pharmaceuticals Inc filed Critical Reliant Pharmaceuticals Inc
Publication of MX2007006775A publication Critical patent/MX2007006775A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe una composicion farmaceutica en una forma de dosis unitaria de fenofibrato y un sistema de solvente de esteres de acido graso, en donde el fenofibrato substancialmente se disuelve en el sistema de solvente.
MX2007006775A 2004-12-06 2005-12-05 Composiciones estables de fenofibrato con esteres de acido graso. MX2007006775A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63312604P 2004-12-06 2004-12-06
PCT/US2005/044036 WO2006062933A2 (en) 2004-12-06 2005-12-05 Stable compositions of fenofibrate with fatty acid esters

Publications (1)

Publication Number Publication Date
MX2007006775A true MX2007006775A (es) 2008-02-25

Family

ID=36578470

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007006775A MX2007006775A (es) 2004-12-06 2005-12-05 Composiciones estables de fenofibrato con esteres de acido graso.

Country Status (12)

Country Link
US (1) US20060188529A1 (es)
EP (1) EP1830804A2 (es)
JP (1) JP2008522972A (es)
KR (1) KR20070098855A (es)
CN (1) CN101094647A (es)
AU (1) AU2005314197A1 (es)
BR (1) BRPI0518426A2 (es)
CA (1) CA2589656A1 (es)
EA (1) EA200701228A1 (es)
MX (1) MX2007006775A (es)
NO (1) NO20073457L (es)
WO (1) WO2006062933A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007001558A (es) * 2004-08-06 2008-03-13 Transform Pharmaceuticals Inc Formulaciones novedosas de fenofibrato y metodos de tratamiento relacionados.
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
CA2746887C (en) 2008-12-15 2016-07-05 Banner Pharmacaps, Inc. Methods for enhancing the release and absorption of water insoluble active agents
AU2010206549B2 (en) * 2009-01-26 2016-08-25 Dcb-Usa, Llc Use of pterosin compounds for treating diabetes and obesity
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
CA2916208A1 (en) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
FR2737121B1 (fr) * 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
AU743098B2 (en) * 1997-12-10 2002-01-17 Cyclosporine Therapeutics Limited Pharmaceutical compositions containing an omega-3 fatty acid oil
US6814977B1 (en) * 1998-12-18 2004-11-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US7014864B1 (en) * 1998-12-18 2006-03-21 Abbott Laboratories Formulations comprising lipid-regulating agents
JP2002532539A (ja) * 1998-12-18 2002-10-02 アボット・ラボラトリーズ 脂質調節剤を含む新規な製剤
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
JP2002540174A (ja) * 1999-03-31 2002-11-26 アボット・ラボラトリーズ 脂質調節剤を含有する新規製剤
US6372251B2 (en) * 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
FR2803203B1 (fr) * 1999-12-31 2002-05-10 Fournier Ind & Sante Nouvelles formulations galeniques du fenofibrate
US6667064B2 (en) * 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
US20040005339A1 (en) * 2002-06-28 2004-01-08 Shojaei Amir H. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability

Also Published As

Publication number Publication date
CA2589656A1 (en) 2006-06-15
EA200701228A1 (ru) 2007-12-28
WO2006062933A3 (en) 2006-08-31
AU2005314197A1 (en) 2006-06-15
NO20073457L (no) 2007-09-05
BRPI0518426A2 (pt) 2008-11-25
WO2006062933A2 (en) 2006-06-15
CN101094647A (zh) 2007-12-26
KR20070098855A (ko) 2007-10-05
EP1830804A2 (en) 2007-09-12
JP2008522972A (ja) 2008-07-03
US20060188529A1 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
MX2007011031A (es) Tratamiento con estatina y acidos grasos omega-3 y un producto de combinacion de los mismos.
EA201290596A1 (ru) Фармацевтический состав, содержащий один или более эфиров фумаровой кислоты в разлагаемой матрице
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
MX2021002553A (es) Metodos para reducir el riesgo de eventos cardiovasculares en un sujeto.
NO20073457L (no) Stabile sammensetninger av fenofibrat med fettsyreestere
EP4342546A3 (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
IL191312A0 (en) Oral pharmaceutical dosage form comprising as active ingredients a proton pump inhibitor together with acetyl salicyclic acid
TW200631597A (en) External use preparation and adhesive preparation thereof
WO2006086108A3 (en) Use of inhibitors of soluble epoxide hydrolase to synergize activity of cox and 5-lox inhibitors
TW200626558A (en) Indazolone derivatives
UY29395A1 (es) Formulación de medicamentos conteniendo vardenafilo.
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
EP1595539A4 (en) DRUGS TO REDUCE THE SIDE EFFECTS OF RIBAVIRIN INTERFERON COMBINATION THERAPY
JP2007238598A5 (es)
WO2007018588A8 (en) Stable pharmaceutical composition comprising linezolid form iv
GEP20125464B (en) Dha esters and use thereof in treatment and prevention of cardiovascular disease
PE20011223A1 (es) Composicion farmaceutica que comprende pemetrexed y un antioxidante como monotioglicerol, l-cisteina y acido tioglicolico
EP2515912A4 (en) PHARMACEUTICAL COMPOSITION WITH VITAMIN D ANALOGON AND COLOSTERS-TENSID MIXTURE
CY1108231T1 (el) Σταθερη στερεα δοσολογικη μορφη περιλαμβανουσα δεσμοπρεσσινη
MX2012007225A (es) Composicion farmaceutica que comprende mezcla de solventes y derivado o analogo de vitamina d.
ITMI20040347A1 (it) Nuovo farmaco di associazione
GEP20125570B (en) Use of indazolemethoxyalkanoic acid for reducing levels of triglycerides, cholesterol and glucose
MX2007006908A (es) Estabilizacion de esteres de glucocorticoides con acidos.
NO20055601L (no) Farmasoytisk preparat i form av en hydrogel for transdermal administrasjon av aktive virkestoffer
AU2005238141A8 (en) Pentenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof